NN-8828是靶向细胞因子IL-21的潜在“first-in-class"高亲和力单克隆抗体,由诺和诺德在非皮肤科适应症中开发至临床2期阶段。NN-8828有潜力阻断IL-21下游信号通路的激活,并抑制该细胞因子在多种免疫细胞中诱导的病理生理功能。这种差异化机制使NN-8828成为治疗炎症和自身免疫性皮肤病的潜在疗法。 根据该协议,Almirall将加速该资产的开发,以解决关键的皮肤病问题,并负责这些适应症的全球开发和商业化活动。诺和诺德将收到预付款以及额外的开发和商业里程碑款项。 Almirall是一家专注于皮肤科适应症的的全球医药公司。根据行业媒体BioSpace报道,NN-8828将可能用于与Almirall管线中以lebrikizumab为基础的一系列皮肤病联合疗法的开发。Lebrikizumab目前正在欧盟接受用于治疗特应性皮炎的监管审评。Almirall于2019年6月从Dermira获得了lebrikizumab的欧洲权利。 [1] Almirall licenses an anti-IL-21 monoclonal antibody from Novo Nordisk to develop it as a first-in-class agent in dermatology. Retrieved February 19, 2024 from https://www.almirall.com/newsroom/news/almirall-licenses-an-anti-il-21-monoclonal-antibody-from-novo-nordisk-to-develop-it-as-a-first-in-class-agent-in-dermatology
[2] Novo Licenses to Almirall Potential First-in-Class Antibody Candidate. Retrieved February 19, 2024 from https://www.biospace.com/article/novo-licenses-to-almirall-potential-first-in-class-antibody-candidate-in-dermatology/